The CRC Digest

Curated CRC research — accessible, accurate, actionable

Saturday, May 23, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ KRAS and BRAF mutations modify adjuvant chemotherapy benefit in early-stage colorectal cancer

  A new study shows that KRAS and BRAF mutations influence how well patients respond to different chemotherapy regimens after surgery for stage II and III colorectal cancer, suggesting these mutations could help personalize adjuvant treatment decisions. (NPJ Precision Oncology)

• ▪ Earlier ctDNA detection after surgery predicts recurrence and identifies who benefits from adjuvant therapy

  Researchers developed a rapid blood test that detects circulating tumor DNA as early as 5 days after surgery for stage II-III colorectal cancer, accurately predicting which patients will experience recurrence and helping guide adjuvant chemotherapy decisions. (NPJ Precision Oncology)

• ▸ Genetic and non-genetic resistance mechanisms coexist in KRAS-inhibitor-treated colorectal cancer

  Analysis of patient biopsies after treatment with KRAS and EGFR inhibitors reveals that acquired genetic mutations are often subclonal and coexist with transcriptional adaptive states, with mesenchymal, YAP, and fetal-like signatures predominating in resistant tumors. (Cancer Cell)

• ◆ Meta-analysis quantifies benefits and risks of single versus dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer

  A comprehensive meta-analysis of randomized trials evaluates the comparative efficacy and safety of immune checkpoint inhibitor monotherapy versus dual immunotherapy in patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer. (BMC Cancer)

• ♥ Survivorship programs improve quality of life for colorectal cancer survivors

  A systematic review and meta-analysis of 22 randomized trials involving nearly 3,000 colorectal cancer survivors found that survivorship programs effectively enhance health-related quality of life. (Supportive Care in Cancer)

These findings continue to refine our understanding of colorectal cancer biology and treatment—bringing us closer to more personalized, effective care for every patient.